Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions

BACKGROUND: The complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod. On the other hand, conventional surgical large loop exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulrahman, Ziena, Hendriks, Natasja, J Kruse, Arnold, Somarakis, Antonios, J M van de Sande, Anna, J van Beekhuizen, Heleen, M J Piek, Jurgen, de Miranda, Noel F C C, Kooreman, Loes F S, F M Slangen, Brigitte, van der Burg, Sjoerd H, de Vos van Steenwijk, Peggy J, van Esch, Edith M G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639137/
https://www.ncbi.nlm.nih.gov/pubmed/36323430
http://dx.doi.org/10.1136/jitc-2022-005288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639137/
https://www.ncbi.nlm.nih.gov/pubmed/36323430
http://dx.doi.org/10.1136/jitc-2022-005288

Ejemplares similares